David Hutton

By crossing into the retina, researchers have found a new DHA supplement achieves what previous ones could not.

The Centers for Medicare and Medicaid Services accepted comments on the proposed rule and several organizations, including the American Academy of Ophthalmology, chimed in with comments and offered suggestions.

A team of researchers at Buck Institute, working with Google Health and Zuckerberg San Francisco General Hospital, are studying the eye as a window into human aging.

The partnership will offer specialty physician practices across retina and other specialties access to SamaCare's platform.

According to a team of researchers at UCLA, the “dormant” cone photoreceptors might actually continue to drive retinal activity for vision.

The FDA has approved enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with CEP290 gene mutations.

According to the company, UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm.

The company is advancing AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy.

According to researchers at the Max Planck Institute, the Kynurenine pathway is not only important for eye pigment formation, it also plays a role in maintaining retinal health.

Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

According to researchers, diabetes mellitus is caused by higher levels of blood glucose due to the lack of production of insulin by the body, resistance to insulin, or both.

Researchers are using a new, highly versatile form of CRISPR-based genome editing with the potential to correct a wide variety of disease-causing genetic mutations.

PBM treatment showed a statistically significant slowing of disease progression in patients with early to intermediate dry AMD.

To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.

The results support plan to advance lead program in ABCA4-related retinopathies into the clinic in 2024 and expansion into other ophthalmology indications.

According to a University of Florida Health, the researchers used gene therapy to both knock down and replace malfunctioning genetic material that affects light-sensing photoreceptors in the retina.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

For this study, researchers focused on photoreceptor cells (PRCs), which are light-detecting cells found in the retina.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.

There are now treatments available that target VEGF to prevent vessel overgrowth, and they often provide dramatic benefits at first. Unfortunately, these benefits can fade with time.

Cedars-Sinai investigators map changes to the retina that correspond to brain changes in the early stage, opening a path to earlier diagnosis.

MCO-010 has been granted orphan drug designation by the FDA for both diseases and multiple mid- to late-stage clinical trials are ongoing.

According to the company, the award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy.

David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

Iveric Bio announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.